| Literature DB >> 27928147 |
Yanxia Li1, Zhaoxia Ding2, Chuanzhong Wu1.
Abstract
BACKGROUND This study examined the effect of kaempferol on uterine fibroids in vitro and the underlying mechanism, and investigated the potential of kaempferol as a clinical drug for the treatment of uterine fibroids. MATERIAL AND METHODS Uterine fibroid tissue and surrounding smooth muscle tissue were collected for primary culture. Different concentrations of kaempferol (12 μM, 24 μM, and 48 μM) were used to treat the cells for 24, 48, and 72 hours. Ethanol was used in the control group. A CCK-8 colorimetric assay was used to detect cell proliferation. Real-time PCR and immunoblot were used to detect estrogen receptor (ER), insulin-like growth factor-1 (IGF-1), and vascular endothelial growth factor (VEGF) levels in mRNA and protein. RESULTS The differences in proliferation at different time points and concentrations of kaempferol were statistically significant. The inhibitory effect of kaempferol on mRNA levels of ER and IGF, and protein levels of ER, VEGF, and IGF-1 were positively correlated with kaempferol concentration. Changes in kaempferol concentration showed no effect on VEGF mRNA expression. Treatment with kaempferol significantly lowered myocardin levels in uterine fibroid tissue compared to normal uterine smooth muscle (P<0.05). CONCLUSIONS Kaempferol might be used for clinical treatment of uterine fibroids due to its inhibitory effect on the proliferation of uterine fibroids cells.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27928147 PMCID: PMC5153323 DOI: 10.12659/msm.898127
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Primer sequences for RT-PCR.
| mRNA | DNA sequences | PCR product |
|---|---|---|
| ER | F 5′-TGCCAAGGAGACTCGCTAG-3′ | 249bp |
| IGF-1 | F 5′-GCTGGTGGATGCTCTTCAGTTC-3′ | 184bp |
| VEGF | F 5′-GCAGAATCATCATCACGAAGTGGT-3′ | 253bp |
Effects of kaempferol on the proliferation of uterine fibroids.
| Group | 24 h | 48 h | 72 h | |||
|---|---|---|---|---|---|---|
| A450 | PI | A450 | PI | A450 | PI | |
| Control | 0.857±0.051 | – | 0.872±0.055 | – | 0.916±0.028 | – |
| Kaempferol group | ||||||
| 12 μml/L | 0.867±0.033 | 89.7 | 0.659±0.052 | 75.7 | 0.762±0.059 | 83. 4 |
| 24 μml/L | 0.657±0.038 | 78.1 | 0.622±0.029 | 72.4 | 0.690±0.035 | 75. 6 |
| 48 μml/L | 0.549±0.051 | 64.5 | 0.603±0.023 | 68.3 | 0.619±0.034 | 68. 4 |
Compared to control group, P<0.05;
Compared to the group of 12 μmol/L with the same treatment time, P<0.05;
Compared to the group of 24 μmol/L with the same treatment time, P<0. 05;
Compared to the group of 24 hours treatment, P<0.05;
Compared to the group of 24 hours treatment, P<0.05.
Effect of kaempferol on the mRNA expression of ER, IGF-1, and VEGF.
| Group | ER mRNA | IGF-1 mRNA | VEGF mRNA |
|---|---|---|---|
| Control | 1.273±0.026 | 1.046±0.028 | 1.283±0.016 |
| Kaempferol group | |||
| 12 μml/L | 1.036±0.013 | 0.916±0.026 | 0.847±0.062 |
| 24 μml/L | 0.845±0.050 | 0.733±0.060 | 0.745±0.034 |
| 48 μml/L | 0.712±0.053 | 0.651±0.013 | 0.733±0.045 |
Compared to control group, P<0.05;
Compared to 12 μmol/L group, P<0.05;
Compared to 24 μmol/L group, P<0.05;
No significant difference between groups of different concentrations of kaempferol, P>0.05.
Figure 1Effect of kaempferol on the mRNA levels of ER, IGF-1, and VEGF. (A) ER mRNA; (B) IGF-1 mRNA; (C) VEGF mRNA.
Effect of kaempferol on the protein levels of ER, IGF-1, and VEGF.
| Protein | Control | 12 μml/L | 24 μml/L | 48 μml/L |
|---|---|---|---|---|
| VEGF | 1 | 0.735±0.055 | 0.626±0.036 | 0.396±0.033 |
| IGF | 1 | 0.615±0.064 | 0.464±0.055 | 0.203±0.025 |
| ER | 1 | 0.926±0.047 | 0.876±0.012 | 0.624±0.066 |
| β-actin | 1 | 1 | 1 | 1 |
Compared to control group, P<0.05;
Compared to 12 μmol/L group, P<0.05;
Compared to 24μmol/L group, P<0.05.
Figure 2Effect of kaempferol on the protein levels of ER, IGF-1, and VEGF.
Figure 3Myocardin has a lower expression level in uterine fibroids. HM – human uterine smooth muscle tissue; HL – human uterine fibroids.